Beneficial effects of lycopene against haloperidol induced orofacial dyskinesia in rats: Possible neurotransmitters and neuroinflammation modulation

被引:39
作者
Datta, Swati [1 ]
Jamwal, Sumit [1 ,2 ]
Deshmukh, Rahul [1 ]
Kumar, Puneet [1 ]
机构
[1] ISF Coll Pharm, Dept Pharmacol, Moga 142001, Punjab, India
[2] IK Gujral Punjab Tech Univ, Jalandhar, India
关键词
Choreiforiic; Neuroprotective; Lycopene; Haloperidol; Oral dyskinesia; Vacuous chewing movements; TARDIVE-DYSKINESIA; ANTIOXIDANT; MODEL; NEUROTOXICITY; IMPAIRMENT; OXIDATION;
D O I
10.1016/j.ejphar.2015.12.032
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Tardive Dyskinesia is a severe side effect of chronic neuroleptic treatment consisting of abnormal involuntary movements, characterized by orofacial dyskinesia. The study was designed to investigate the protective effect of lycopene against haloperidol induced orofacial dyskinesia possibly by neurochemical and neuroinflammatory modulation in rats. Rats were administered with haloperidol (1 mg/kg, i.p for 21 days) to induce orofacial dyskinesia. Lycopene (5 and 10 mg/kg, p.o) was given daily 1 hour before haloperidol treatment for 21 days. Behavioral observations (vacuous chewing movements, tongue protrusions, facial jerking, rotarod activity, grip strength, narrow beam walking) were assessed on 0th, 7th 14th 21st day after haloperidol treatment. On 22nd day, animals were killed and striatum was excised for estimation of biochemical parameters (malondialdehyde, nitrite and endogenous enzyme (GSH), proinflammatory cytokines [Tumor necrosis factor, Interleukin 1 beta, Interleukin 6] and neurotransmitters level (dopamine, serotonin, nor epinephrine, 5-Hydroxyindole acetic acid (5-HIAA), Homovanillic acid, 3,4-dihydroxyphenylacetic acid. Haloperidol treatment for 21 days impaired muscle co-ordination, motor activity and grip strength with an increased in orofacial dyskinetic movements. Further free radical generation increases MDA and nitrite levels, decreasing GSH levels in striatum. Neuroinflammatory markers were significantly increased with decrease in neurotransmitters levels. Lycopene (5 and 10 mg/kg, p.o) treatment along with haloperidol significantly attenuated impairment in behavioral, biochemical, neurochemical and neuroinflammatory markers. Results of the present study attributed the therapeutic potential of lycopene in the treatment (prevented or delayed) of typical antipsychotic induced orofacial dyskinesia. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:229 / 235
页数:7
相关论文
共 36 条
[1]  
Agarwal S, 2000, CAN MED ASSOC J, V163, P739
[2]   Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats - Implications for tardive dyskinesia? [J].
Andreassen, OA ;
Jorgensen, HA .
PROGRESS IN NEUROBIOLOGY, 2000, 61 (05) :525-541
[3]   Lycopene oxidation product enhances gap junctional communication [J].
Aust, O ;
Ale-Agha, N ;
Zhang, L ;
Wollersen, H ;
Sies, H ;
Stahl, W .
FOOD AND CHEMICAL TOXICOLOGY, 2003, 41 (10) :1399-1407
[4]   Protein thiol oxidation by haloperidol results in inhibition of mitochondrial complex I in brain regions: comparison with atypical antipsychotics [J].
Balijepalli, S ;
Kenchappa, RS ;
Boyd, MR ;
Ravindranath, V .
NEUROCHEMISTRY INTERNATIONAL, 2001, 38 (05) :425-435
[5]   Activation of striatal inflammatory mediators and caspase-3 is central to haloperidol-induced orofacial dyskinesia [J].
Bishnoi, Mahendra ;
Chopra, Kanwaijit ;
Kulkarni, Shrinivas K. .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 590 (1-3) :241-245
[6]   Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia - A biochemical and neurochemical study [J].
Bishnoi, Mahendra ;
Chopra, Kanwaljit ;
Kulkarni, Shrinivas K. .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2007, 31 (05) :1130-1138
[7]  
Bishnoi M, 2007, INDIAN J EXP BIOL, V45, P175
[8]   Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes [J].
Bishnoi, Mahendra ;
Chopra, Kanwaljit ;
Kulkarni, Shrinivas K. .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 552 (1-3) :55-66
[9]   Oxidative stress and tardive dyskinesia: Pharmacogenetic evidence [J].
Cho, Chul-Hyun ;
Lee, Heon-Jeong .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2013, 46 :207-213
[10]   Tardive dyskinesia and new antipsychotics [J].
Correll, Christoph U. ;
Schenk, Eva M. .
CURRENT OPINION IN PSYCHIATRY, 2008, 21 (02) :151-156